Literature DB >> 25993267

Establishment of a human multiple myeloma xenograft model in the chicken to study tumor growth, invasion and angiogenesis.

Agnieszka Martowicz1, Johann Kern2, Eberhard Gunsilius3, Gerold Untergasser4.   

Abstract

Multiple myeloma (MM), a malignant plasma cell disease, remains incurable and novel drugs are required to improve the prognosis of patients. Due to the lack of the bone microenvironment and auto/paracrine growth factors human MM cells are difficult to cultivate. Therefore, there is an urgent need to establish proper in vitro and in vivo culture systems to study the action of novel therapeutics on human MM cells. Here we present a model to grow human multiple myeloma cells in a complex 3D environment in vitro and in vivo. MM cell lines OPM-2 and RPMI-8226 were transfected to express the transgene GFP and were cultivated in the presence of human mesenchymal cells and collagen type-I matrix as three-dimensional spheroids. In addition, spheroids were grafted on the chorioallantoic membrane (CAM) of chicken embryos and tumor growth was monitored by stereo fluorescence microscopy. Both models allow the study of novel therapeutic drugs in a complex 3D environment and the quantification of the tumor cell mass after homogenization of grafts in a transgene-specific GFP-ELISA. Moreover, angiogenic responses of the host and invasion of tumor cells into the subjacent host tissue can be monitored daily by a stereo microscope and analyzed by immunohistochemical staining against human tumor cells (Ki-67, CD138, Vimentin) or host mural cells covering blood vessels (desmin/ASMA). In conclusion, the onplant system allows studying MM cell growth and angiogenesis in a complex 3D environment and enables screening for novel therapeutic compounds targeting survival and proliferation of MM cells.

Entities:  

Mesh:

Year:  2015        PMID: 25993267      PMCID: PMC4542136          DOI: 10.3791/52665

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  35 in total

1.  The gelatin sponge-chorioallantoic membrane assay.

Authors:  Domenico Ribatti; Beatrice Nico; Angelo Vacca; Marco Presta
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

2.  A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma.

Authors:  Dharminder Chauhan; Ajita V Singh; Monette Aujay; Christopher J Kirk; Madhavi Bandi; Bryan Ciccarelli; Noopur Raje; Paul Richardson; Kenneth C Anderson
Journal:  Blood       Date:  2010-08-30       Impact factor: 22.113

3.  Engineering tumors with 3D scaffolds.

Authors:  Claudia Fischbach; Ruth Chen; Takuya Matsumoto; Tobias Schmelzle; Joan S Brugge; Peter J Polverini; David J Mooney
Journal:  Nat Methods       Date:  2007-09-02       Impact factor: 28.547

Review 4.  Mechanisms and clinical prospects of Notch inhibitors in the therapy of hematological malignancies.

Authors:  Yulia Nefedova; Dmitry Gabrilovich
Journal:  Drug Resist Updat       Date:  2008-10-31       Impact factor: 18.500

5.  Chick ex ovo culture and ex ovo CAM assay: how it really works.

Authors:  Daniel S Dohle; Susanne D Pasa; Sebastian Gustmann; Markus Laub; Josef H Wissler; Herbert P Jennissen; Nicole Dünker
Journal:  J Vis Exp       Date:  2009-11-30       Impact factor: 1.355

6.  GRP-78 secreted by tumor cells blocks the antiangiogenic activity of bortezomib.

Authors:  Johann Kern; Gerold Untergasser; Christoph Zenzmaier; Bettina Sarg; Guenther Gastl; Eberhard Gunsilius; Michael Steurer
Journal:  Blood       Date:  2009-08-27       Impact factor: 22.113

7.  A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma.

Authors:  Julia Kirshner; Kyle J Thulien; Lorri D Martin; Carina Debes Marun; Tony Reiman; Andrew R Belch; Linda M Pilarski
Journal:  Blood       Date:  2008-06-05       Impact factor: 22.113

8.  Fate of melanoma cells entering the microcirculation: over 80% survive and extravasate.

Authors:  S Koop; I C MacDonald; K Luzzi; E E Schmidt; V L Morris; M Grattan; R Khokha; A F Chambers; A C Groom
Journal:  Cancer Res       Date:  1995-06-15       Impact factor: 12.701

9.  Chapter 2. Chick embryo chorioallantoic membrane models to quantify angiogenesis induced by inflammatory and tumor cells or purified effector molecules.

Authors:  Elena I Deryugina; James P Quigley
Journal:  Methods Enzymol       Date:  2008       Impact factor: 1.600

10.  AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML.

Authors:  Daniel J Pearce; David Taussig; Kazem Zibara; Lan-Lan Smith; Christopher M Ridler; Claude Preudhomme; Bryan D Young; Ama Z Rohatiner; T Andrew Lister; Dominique Bonnet
Journal:  Blood       Date:  2005-10-18       Impact factor: 22.113

View more
  6 in total

1.  CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma.

Authors:  Shanmugapriya Thangavadivel; Claudia Zelle-Rieser; Angelika Olivier; Benno Postert; Gerold Untergasser; Johann Kern; Andrea Brunner; Eberhard Gunsilius; Rainer Biedermann; Roman Hajek; Ludek Pour; Wolfgang Willenbacher; Richard Greil; Karin Jöhrer
Journal:  Oncotarget       Date:  2016-11-29

2.  The avian chorioallantoic membrane as an alternative tool to study medullary thyroid cancer.

Authors:  Nassim Ghaffari-Tabrizi-Wizsy; Christina Angelika Passegger; Laura Nebel; Fabian Krismer; Gudrun Herzer-Schneidhofer; Gert Schwach; Roswitha Pfragner
Journal:  Endocr Connect       Date:  2019-05-01       Impact factor: 3.335

3.  Optimization of the chicken chorioallantoic membrane assay as reliable in vivo model for the analysis of osteosarcoma.

Authors:  Pierre Kunz; Astrid Schenker; Heiner Sähr; Burkhard Lehner; Jörg Fellenberg
Journal:  PLoS One       Date:  2019-04-15       Impact factor: 3.240

4.  Spliced XBP1 Levels Determine Sensitivity of Multiple Myeloma Cells to Proteasome Inhibitor Bortezomib Independent of the Unfolded Protein Response Mediator GRP78.

Authors:  Bojana Borjan; Johann Kern; Normann Steiner; Eberhard Gunsilius; Dominik Wolf; Gerold Untergasser
Journal:  Front Oncol       Date:  2020-01-22       Impact factor: 6.244

5.  A Poly-(ethylene glycol)-diacrylate 3D-Printed Micro-Bioreactor for Direct Cell Biological Implant-Testing on the Developing Chicken Chorioallantois Membrane.

Authors:  Eric Lutsch; Andreas Struber; Georg Auer; Thomas Fessmann; Günter Lepperdinger
Journal:  Micromachines (Basel)       Date:  2022-07-31       Impact factor: 3.523

Review 6.  Applications of Gene Editing in Chickens: A New Era Is on the Horizon.

Authors:  Hicham Sid; Benjamin Schusser
Journal:  Front Genet       Date:  2018-10-09       Impact factor: 4.599

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.